Blocking interleukin-1 and tumor necrosis factor in disease

European Cytokine Network

Volumn 8, Issue 3, 1997, Pages 294-296

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR;

CONFERENCE PAPER; HUMAN; INFLAMMATION; NONHUMAN; SEPSIS;

ANIMALS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030782402     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Fong Y, Tracey K J, Moldauer L L, Hesse D G, Manogue K B, Kenney J S, Lee A T, Kuo G C, Allison A C, Lowry S F, Cerami A. 1989. Antibodies to cachectin/tumor necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J. Exp. Med. 170 :1627.
2. Wakabayashi G, Gelfand J A, Burke J F, Thompson R C, Dinarello C A. 1991. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits FASEB J. 5: 338.
3. Wolff S M. 1973. Biological effects of bacterial endotoxins in man. J. Infect. Dis. 128 (suppl.): 733.
4. Wallach D, Holtmann H, Engelmann H, Nophar Y. 1988. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. (Review) J. Immunol. 140: 2994.
5. Dinarello C A. 1996. Biological basis for interleukin-1 in disease. (Review) Blood 87: 2095.
6. Elliott M J, Maini R N, Feldmann M, Kalden J R, Antoni C, Smolen J S, Leeb B, Breedveld F C, Macfarlane J D, Long-Fox A, Charles P, Bijl H, Woody J N. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105.
7. Lebsack M E, Paul C C, Martindale J J, Catalano M. 1993. A dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 36: S39.
8. Bresnihan B, Lookabaugh J, Witt K, Musikic P. 1996. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized, double-blind, placebo-controlled multicenter trial. Arthritis Rheum. 39:S73 (abs).
9. Watt I, Cobby M. 1996. Recombinant human interleukin-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis. Arthritis Rheum. 39: S123.
10. Van Dullemen H M, Van Deventer S J, Hommes D W, Bijl H A, Jansen J, Tytgat G N, Woody J. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129.
11. Antin J H, Weinstein H J, Guinan E C, McCarthy P, Bierer B E, Gilliland D G, Parsons S K, Ballen K K, Rimm I J, Falzarano G, Ferrara J L. 1994. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84: 1342.
12. Zeni F, Freeman B, Natanson C. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25: 1095.